Genocea Biosciences (GNCAQ) 10-Q2019 Q2 Quarterly report

Filed: 25 Jul 19, 8:49am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: accrual, accuracy, administered, American, antitumor, Appellate, assay, aware, Barry, broad, capable, Carroll, central, chapter, check, choosing, COBRA, Code, commented, Commission, Compensatory, complying, conclusion, contemplate, deadline, decide, Departure, detected, effector, effort, Egleston, electronically, elicited, eliciting, emerging, Exhibit, expressed, extension, filer, finally, Food, function, furnished, Gainey, goal, good, hereto, implied, impractical, imprudent, inhibitory, Interactive, irrelevant, label, lieu, listed, mark, McKenna, memory, metastatic, monotherapy, notwithstanding, open, opening, optimal, Pamela, passage, past, PCT, placeholder, preceding, prejudice, preliminary, President, previously, Procedure, progression, promoted, quickly, ratio, reinforcing, release, reliable, reliance, repertoire, request, resolution, resolved, retroactively, reverse, revise, revised, Rosen, safety, shell, shorter, Shortly, signal, Similarly, smaller, Society, solid, split, statistical, stimulation, suggesting, Telephone, text, tolerated, trade, undue, unknown, unvested, verified, Vice, vitro, vivo, voluntary

Removed: amortized, anniversary, applicable, applying, assessment, attachment, bankruptcy, building, capitalized, Chief, considerable, continuing, covenant, deprioritized, disposition, divided, duration, excise, exercisable, expire, expiring, extending, failure, false, formed, funded, Global, grant, Hetherington, independent, insolvency, involving, Jonathan, leader, lower, medical, misleading, modification, Nasdaq, newly, occupied, occurred, October, original, overcome, Poole, prepared, prepay, recalculation, registration, relapse, remain, remaining, renewal, repaid, representation, resale, resold, restrict, scientific, separate, Seth, thereunder, twelve, unpaid, utilize, written

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated GNCAQ transcripts

GNCAQ similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Genocea Biosciences, Inc. (the “Company”) for the period ended June 30, 2019 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, the undersigned, Diantha Duvall, as the Principal Financial Officer of the Company, do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:


(1)	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and


(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.



	/s/ DIANTHA DUVALL
	Diantha Duvall
	Chief Financial Officer (Principal Financial and Accounting Officer)

Date: July 25, 2019

*A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

The foregoing certification is being furnished solely pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code) and is not being filed as part of the Form 10-Q or as a separate disclosure document.